ChiCTR2300071185 版本V1.0 版本创建时间2023/05/06 17:54:07 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300071185 

最近更新日期:

Date of Last Refreshed on:

2023-05-06 17:54:04 

注册时间:

Date of Registration:

2023-05-06 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

基于可视化立体定向系统治疗微创术后肾残留碎石的临床研究

Public title:

To study the clinical application of visualization stereotactic system in the treatment of residual renal calculi after minimally invasive surgery

注册题目简写:

体位引流碎石系统的临床应用

English Acronym:

Clinical application of postural drainage lithotripsy system

研究课题的正式科学名称:

基于可视化体位引流碎石系统治疗微创术后肾残留碎石的临床研究

Scientific title:

Clinical study of the treatment of residual renal calculi after minimally invasive surgery based on the visual position drainage lithotripsy system

研究课题代号(代码):

Study subject ID:

CMCC202211

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

CMCC202211

申请注册联系人:

戴亮亮 

研究负责人:

史红雷 

Applicant:

Liangliang Dai  

Study leader:

Honglei Shi  

申请注册联系人电话:

Applicant telephone:

+8613776466079

研究负责人电话:

Study leader's
telephone:

+8613861287151

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1165145250@qq.com

研究负责人电子邮件:

Study leader's E-mail:

dashi7810@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省常州市天宁区永宁北路2号常州市武进人民医院

研究负责人通讯地址:

江苏省常州市天宁区永宁北路2号常州市武进人民医院

Applicant address:

Changzhou Wujin People's Hospital, 2 Yongning North Road, Tianning District, Changzhou City, Jiangsu Province

Study leader's address:

Changzhou Wujin People's Hospital, 2 Yongning North Road, Tianning District, Changzhou City, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

常州市武进人民医院

Applicant's institution:

Changzhou Wujin People's Hospital

研究负责人所在单位:

常州市武进人民医院

Affiliation of the Leader:

Changzhou Wujin People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022-SR-70

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

常州市武进人民医院

Name of the ethic committee:

Changzhou Wujin People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022-02-16 00:00:00

伦理委员会联系人:

张海燕

Contact Name of the ethic committee:

Haiyan Zhang

伦理委员会联系地址:

江苏省常州市天宁永宁北路2号常州市武进人民医院6号楼1楼伦理办公室

Contact Address of the ethic committee:

Ethics Office, 1st Floor, Building 6, Changzhou Wujin People's Hospital, 2 North Yongning Road, Tianning, Changzhou, Jiangsu

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86051985579190

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

常州市武进人民医院

Primary sponsor:

Changzhou Wujin People's Hospital

研究实施负责(组长)单位地址:

江苏省常州市天宁区永宁北路2号常州市武进人民医院

Primary sponsor's address:

Changzhou Wujin People's Hospital, 2 Yongning North Road, Tianning District, Changzhou City, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

常州市

Country:

China

Province:

Jiangsu

City:

Changzhou

单位(医院):

常州市武进人民医院

具体地址:

江苏省常州市天宁区永宁北路2号常州市武进人民医院

Institution
hospital:

Changzhou Wujin People's Hospital

Address:

Changzhou Wujin People's Hospital, 2 Yongning North Road, Tianning District, Changzhou City, Jiangsu Province

经费或物资来源:

2022年江苏省研究生实践创新计划基金资助(SJCX22_1880);2022年度南京医科大学常州医学中心临床研究项目基金资助(CMCC202211)

Source(s) of funding:

Jiangsu Graduate Practice Innovation Plan in 2022 (SJCX22_1880); Clinical Research Project of Changzhou Medical Center of Nanjing Medical University in 2022 (CMCC202211)

研究疾病:

泌尿结石  

Target disease:

urinary calculus

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

单臂 

Study design:

Single arm 

研究目的:

本研究旨在通过自主研发数字建模软件和立体定向排石床找出一种处理微创治疗后肾内残余碎石的系统方法,提高微创手术后肾内残余碎石的排出率,减少临床相关不良事件的发生并切实降低术后结石的复发率,从而降低人群疾病的发生,提高健康状况,减轻医保负担,促进全面健康。  

Objectives of Study:

The purpose of this study is to find out a systematic method to manage residual lithotripsy after minimally invasive surgery by self-developed digital modeling software and stereotactic stone discharge bed, so as to improve the discharge rate of residual lithotripsy after minimally invasive surgery, reduce the occurrence of clinically relevant adverse events and effectively reduce the recurrence rate of postoperative stones, so as to reduce the occurrence of disease, improve health status, and reduce the burden of medical insurance. Promoting overall health.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

选取由2022年2月至2023年2月行RIRS手术的泌尿结石患者,同时所有患者均由同一名外科医生主刀且在RIRS术后1-3天经过CT确定有RFs的患者20例。

Inclusion criteria

From February 2022 to February 2023, 20 patients with urinary calculi who underwent RIRS surgery were selected. At the same time, all patients were operated by the same surgeon and were confirmed to have RFs by CT 1-3 days after RIRS.

排除标准:

排出标准:结石下有尿路梗阻、泌尿系统狭窄或畸形、妊娠或月经期、未控制的高血压、既往有脑血管意外病史以及青光眼病史患者。

Exclusion criteria:

Exclusion criteria: patients with urinary tract obstruction under the stone, urinary tract stenosis or malformation, pregnancy or menstruation, uncontrolled hypertension, previous history of cerebrovascular accident and glaucoma.

研究实施时间:

Study execute time:

From 2022-02-16 00:00:00 To 2024-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-03-01 00:00:00 To 2023-03-04 00:00:00

干预措施:

Interventions:

组别:

RIRS术后经CT确认有残留碎石的患者

样本量:

20

Group:

Patients with residual lithotripsy confirmed by CT after RIRS

Sample size:

干预措施:

在RIRS术后第三天进行体位引流碎石系统处理残留碎石

干预措施代码:

Intervention:

A postural drainage lithotripsy system was performed on the third day after RIRS to deal with residual lithotripsy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏省 

市(区县):

常州市 

Country:

China

Province:

Jiangsu province

City:

Changzhou

单位(医院):

常州市武进人民医院 

单位级别:

三甲 

Institution
hospital:

Changzhou Wujin People's Hospital

Level of the institution:

Third class A

测量指标:

Outcomes:

指标中文名:

残留碎石的清除率

指标类型:

主要指标

Outcome:

The clearance rate of residual gravel

Type:

Primary indicator

测量时间点:

RIRS术前、RIRS术后1-3天以及随访结束后

测量方法:

通过CT影像学方法观察肾内残留碎石的变化

Measure time point of outcome:

Before RIRS, 1-3 days after RIRS, and at the end of follow-up

Measure method:

The changes of residual stones in the kidney were observed by CT imaging

指标中文名:

肾功能变化

指标类型:

次要指标

Outcome:

Changes in renal function

Type:

Secondary indicator

测量时间点:

RIRS术前、RIRS术后1-3天以及随访结束后

测量方法:

观察患者血常规的数据报告

Measure time point of outcome:

Before RIRS, 1-3 days after RIRS, and at the end of follow-up

Measure method:

The patient's blood routine data report was observed

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不涉及

Randomization Procedure (please state who generates the random number sequence and by what method):

Not applicable

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

http://www.medresman.org.cn/uc/sindex.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.medresman.org.cn/uc/sindex.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

None

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-05-06 17:54:04